Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113889 | 0.84 | GAA (0.45) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL20113890 | 0.84 | GAA (0.45) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL20113908 | 0.82 | GAA (0.42) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL20113892 | 0.79 | GAA (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL20113524 | 0.77 | MGAM (0.40) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL20113736 | 0.73 | GAA (0.47) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL20109194 | 0.69 | ALDH1A1 (0.34) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13293249 | 0.69 | GAA (0.54) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL20113734 | 0.68 | GAA (0.37) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL10423902 | 0.66 | GAA (0.50) | GAAMGAMSIMGAM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633403-B2 | N-heterocyclic phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | GAA 4181/4885MGAM 4128/4885SI 2996/4885 |
| US-10633403-B2 | N-heterocyclic phosphines | NANP, PPIP5K2, PHPT1 | GAA 4181/4885MGAM 4128/4885SI 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.